Boro Dropulic
博罗·德罗普利奇
PhD
Chief Executive Officer首席执行官
👥Biography 个人简介
Visionary biotech leader pioneering in vivo CAR-T cell generation using lentiviral vectors administered directly to patients, eliminating the need for ex vivo cell manufacturing. His work at Umoja Biopharma aims to make cell therapy universally accessible.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
In Vivo CAR-T Generation
Developed the VivoVec lentiviral platform for direct in vivo T-cell transduction, enabling CAR-T cell generation inside the patient without ex vivo manufacturing steps.
Representative Works 代表性著作
Lentiviral vectors for the treatment of HIV and cancer
Human Gene Therapy (2011)
Foundational review of lentiviral vector systems and their clinical applications in cancer and HIV gene therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Carl H. June
University of Pennsylvania
Michel Sadelain
Memorial Sloan Kettering Cancer Center
Crystal L. Mackall
Stanford University
Katy Rezvani
MD Anderson Cancer Center
关注 博罗·德罗普利奇 的研究动态
Follow Boro Dropulic's research updates
留下邮箱，当我们发布与 Boro Dropulic（Umoja Biopharma）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment